Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World

• Conditions: High Altitude; Covid19

• Registration Number: NCT04604249
• Lead Sponsor: Centre d'Expertise sur l'Altitude EXALT

Brief Summary

Since the beginning of 2020, SARS-CoV-2 outbreak spread over the world, conducting in a pandemic state declared by the world health organization in March 2020. Conflicting data have been yet published regarding to the incidence rate of COVID-19 infection in altitude. Mainly based on analysis from national Peru database, some authors argued that COVID-19 disease, as well as case fatality rate was less frequent in altitude. However, epidemiological data are lacking regarding to the prevalence of COVID-19 in altitude, and more specially in high altitude.

Aim of this cross-sectional study is to assess the prevalence of seroconversion for the SARS-CoV-2 in the population of La Rinconada, a mining town at 5,100 m, the highest city in the world.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-10-25
• Study Start: 2020-10-26
• Study First Submitted QC: 2020-10-26
• Study First Posted: 2020-10-27
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-03
• Last Update Posted: 2021-02-04
• Primary Completion: 2021-11-30
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Age > 18 years.

Exclusion Criteria

• Age < 18 years.
• Inability to give informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Prevalence of seroconversion for SARS-CoV-2.	Through study completion, an average of 1 week

Secondary Outcome Measures

Name	Time	Method
2. Occupational and environmental exposures associated with SARS-CoV-2 seroconversion.	Through study completion, an average of 1 week

Trial Locations

Locations (1)

La Rinconada; 🇵🇪 Puno, Peru